`IPR of U.S. Pat. No. 7,829,595
`
`
`
`1.
`
`1, Jennifer L. Calvert, a resident of Atlanta, Georgia, hereby declare as
`
`follows:
`
`2.
`
`On information and belief, Exhibits 1001-1023 are true and accurate copies
`
`of the original documents, as shown in the table below:
`
`
`
`Patent” or Ex. 1001
`
`1002”
`
`U.S. Patent No. 7,329,595 to Lawrence, er al. (“595
`File History to the 595 Patent (“File History” or “Ex.
`U.S. Patent No. 6,211,244 to Van Wagenen, er al. (“Van
`U.S. Patent No. 5,162,117 to Stupak, et al. (“Stupak” or
`
`
`U.S. PatentNo. 5,879,706 to Carter, etal. (“Carter” or“Ex.
`Canadian Patent Application No. 2,004,565 by Chang, et
`U.S. Patent No. 8,703,196 to Babcock, er al. (“Babcock”
`U.S. Patent No. 6,733,780 to Tyler, et al. (“Tyler” or “Ex.
`
`U.S. Patent No. 4,931,286 to Johnson, et al. (“Johnson”
`I PracticeofPharmaceutics(12thed.)(1994)
`Excerpts from the Handbook ofPharmaceutical
`
`
`
`
`
`
`
`Waenen” or “Ex. 1003”
`
`“Ex. 1004”
`
`
`
`1006”
`
`al. “Chan” or “Ex. 1007”
`
`or “Ex. 1008”
`
`1009”
`
`Ex. 1011
`
`or “Ex. 1010”
`Excerpts from The Pharmaceutical Codex: Principles and
`
`“Pharmaceutical Codex” or “Ex. 1011”
`
`Exci ients 3rd ed.
`
`2000 “I-IPE” or “Ex. 1012”
`
`Ex. 1013
`
`Excerpts from Howard C. Ansel, er al., Pharmaceutical
`Dosage Forms and Drug Delivery Systems (7th ed.)
`1999
`“Ansel” or “Ex. 1013”
`
`
`
`
`Excerpts fi-om Herbert A. Lieberman, Leon Lachman,
`Joseph B. Schwartz (eds.), Pharmaceutical Dosage
`
`Forms: Tablets (2nd ed.) (1989) Vol. 1 (“Lieberman 1” or
`
`
`
`
`
`
`Excerpts from Herbert A. Lieberman, Leon Lachman,
`Joseph B. Schwartz (eds.), Pharmaceutical Dosage
`Fonns: Tablets (2nd ed.) (1989) Vol. 2 (“Lieberman II”
`
`or “Ex. 1015”
`
`
`Particle Size — U.S. Sieve Series and Tyler Mesh Series
`Equivalents (2002; updated 2013), found at
`www.azom.com/article.aspx?ArticleID=1417, last
`
`
`accessed Au ust 7, 2015 “Particle Size” or “Ex. 1016"
`
`
`New Agent Reduces PTH Levels in Hemodialysis
`Patients With Secondary Hyperparathyroidism,
`Formulary (April 2003) Vol. 38, p. 197 (“Forn1ulary” or
`
`
`
` J.C..Chaumeil, Micronization: A Method of Improving
`
`the Bioavailability of Poorly Soluble Drugs, METH.
`
`FIND. EXP. CLIN. PHARMACOL. (1998), pp. 211-215
`“Chaumeil” or “Ex. 1018”
`
`Excerpt fiom Sir Colin Dollery (ed.), Therapeutic Drugs,
`
`
`
`1991 Vol. 2 “Dolle ” or “Ex. 1019”
`Gordon T. Mclnnes, et al., Effect of Micronization on the
`Bioavailability and Pharmacologic Activity of
`Spironolactone, J. CLIN. PHARMACOL. 22 (1982), pp.
`“Mclnnes” or “Ex. 1020”
`
`
`
`
`
`
`
`Ex. 1014
`
`Ex. 1015
`
`Ex. 1017
`
`Ex. 1018
`
`Ex. 1020
`
`Ex. 1021
`Ex. 1022
`
`Ex. 1023
`
`
`
`
`
`
`
`
`Declaration of Walter G. Chambliss, Ph.D. “Ex. 102l”
`Decision Granting Inter Partes Review as to U.S. Patent
`No. 6,821,975 “Ex. 1022”
`Declaration of Jennifer L. Calvert “Ex. 1023”
`
`
`3.
`
`I hereby declare under penalty of perjury under the laws of the United States
`
`of America that the foregoing is true and correct, and that all statements made
`
`of my own knowledge are true and that all statements made on information
`
`and belief are believed to be true. I understand that Willfill false statements
`
`
`
`and the like are punishable by fine or imprisonment, or both (18 U.S.C. §
`
`1001).
`
`Executed on October 26, 2015.
`
`Jennifer L. Calvert